COVID-19 Related Coagulopathy: A Distinct Entity?
Benjamin Marchandot, Laurent Sattler, Laurence Jesel, Kensuke Matsushita, Valérie B. Schini‐Kerth, L. Grunebaum, Olivier Morel
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy.
Topics & Concepts
MedicineCoagulopathyCoronavirus disease 2019 (COVID-19)PandemicIntensive care medicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)EpidemiologyNarrative reviewDiseaseInfectious disease (medical specialty)VirologyPathologyInternal medicineOutbreakCOVID-19 Clinical Research StudiesRetinal and Optic ConditionsCOVID-19 and healthcare impacts